A Phase I/2A trial evaluating NY-303 as a monotherapy for the treatment of hepatocellular carcinoma in patients not responding to first-line immunotherapy
Latest Information Update: 05 Nov 2024
At a glance
- Drugs NY 303 (Primary)
- Indications Carcinoma; Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Oct 2024 According to NAYA Biosciences media release, company announced that it is presenting novel insights into the mode of action of its GPC3-targeting NK engager bispecific antibody NY-303 in this trial at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 6-10 in Houston, Texas.
- 30 Oct 2024 New trial record